Today marks World Hypophosphatasia (HPP) Day, a vital opportunity to raise awareness about this rare bone disease and its impact on patients and their families. Here, at Rampart Bioscience, we're dedicated to advancing medicines for HPP, and grateful for all those striving to improve the lives of those affected. Earlier this year, our Chief Creative Officer Ben Patriquin had the honor of moderating a discussion with Deborah Fowler and Cannon Sittig from Soft Bones, Inc. for the Rampart Team and their families, a remarkable group that supports families navigating the complexities of HPP. Their insights and advocacy remind us of the importance of community and collaboration in our mission.
Rampart Bioscience
Biotechnology Research
Monrovia, California 2,990 followers
Leading a new era of effective, safe and accessible gene medicines.
About us
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies. Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Website
-
RampartBio.com
External link for Rampart Bioscience
- Industry
- Biotechnology Research
- Company size
- 1 employee
- Headquarters
- Monrovia, California
- Type
- Educational
- Founded
- 2019
Locations
-
Primary
Get directions
231 W Chestnut Ave
Monrovia, California 91016, US
Employees at Rampart Bioscience
Updates
-
We’re #hiring a new Controller in Monrovia, California. Apply today or share this post with your network.
-
Rampart Bioscience reposted this
We are actively #hiring! Know anyone who might be interested?